Tender Results of European Commission, Health Emergency Preparedness And Response Authority Hera

The subject matter of the FWC is the supply of up to 100 080 (one hundred thousand and eighty) treatment courses of human pharmaceutical oral dosage form of Tecovirimat which is approved and sold in the United States as 'TPOXX' (US FDA marketing authorisation NDA208627) and/or Tecovirimat SIGA (EMA conditional marketing authorisation (EU/1/21/1600/001) (the 'Product'). Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg: smallpox, monkeypox, cowpox. Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg.